Results 1 to 10 of about 8,272 (178)

Immunoglobulin Light Chain Amyloidosis [PDF]

Clinical Case Reports
Symmetric, purpuric hand nodules and macroglossia prompted skin biopsy revealing immunoglobulin light chain amyloidosis, leading to the diagnosis of multiple myeloma.
Justin Lyon, Ashley Khouri, Katheryn A. Bell, Jamie Zussman   +3 more
doaj   +5 more sources

Localized Immunoglobulin Light-Chain Amyloidosis of the Ulnar Nerve [PDF]

Case Reports in Neurology, 2021
Amyloidosis is a disorder caused by extracellular tissue deposition of insoluble fibrils. Amyloidosis can be divided into systemic or localized disease. Primary systemic amyloidosis is a multisystem disease caused by the deposition of amyloid in various ...
Shinsuke Morisaki, Shinji Tsuchida, Eiichi Konishi, Nagaaki Katoh, Yusuke Takahashi, Kenji Takahashi   +5 more
doaj   +5 more sources

Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans [PDF]

Disease Models & Mechanisms
Abstract Cardiomyopathy determines the prognosis of patients with immunoglobulin light chain (AL) amyloidosis, a rare systemic disease caused by the misfolding and deposition of monoclonal light chains (LCs). The reasons underlining their cardiac tropism remain unknown, and an animal model recapitulating the main ...
Margherita Romeo, Maria Monica Barzago, Alessandro Corbelli, Silvia Maglioni, Natascia Ventura, Carmina Natale, Andrea Conz, Mario Salmona, Giovanni Palladini, Mario Nuvolone, Fabio Fiordaliso, Giampaolo Merlini, Luisa Diomede   +12 more
doaj   +4 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [PDF]

New England Journal of Medicine, 2021
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib ...
Efstathios Kastritis, Giovanni Palladini, Ashutosh D Wechalekar   +2 more
exaly   +11 more sources

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021 [PDF]

Blood Cancer Journal, 2021
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients ...
M. Hasib Sidiqi, Morie A. Gertz
doaj   +2 more sources

Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. [PDF]

J Natl Compr Canc Netw, 2023
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early mortality seen in this disease.
Zanwar S, Gertz MA, Muchtar E.
europepmc   +3 more sources

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics [PDF]

Nature Communications, 2022
Immunoglobulin light chain amyloidosis is a lethal hematologic disorder driven by clonal plasma cells producing abnormal light chains that damage healthy tissues. Fraser et al.
Cameron S. Fraser, Johan K. E. Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Chendi Li, Stacey Yu, Frances Blevins, Aaron N. Hata, Jeffrey W. Miller, Gary A. Bradshaw, Marian Kalocsay, Vaishali Sanchorawala, Shayna Sarosiek, Kristopher A. Sarosiek   +14 more
doaj   +2 more sources

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy [PDF]

Case Reports in Gastrointestinal Medicine, 2021
Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo, Takehito Ito, Jun Nomura, Keigo Murakami, Shiho Kondo, Tomonori Satoh, Daisuke Fukushi, Yuki Yoshino, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kazuhiro Murakami, Junichi Kameoka, Kennichi Satoh   +15 more
doaj   +2 more sources

Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved] [PDF]

F1000Research, 2018
Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction.
Talha Badar, Anita D'Souza, Parameswaran Hari   +2 more
doaj   +2 more sources

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. [PDF]

Hemasphere
Abstract Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy.
Carpinteiro A, Kimmich C, Trajanova D, Hegenbart U, Hansen T, Holtick U, von Landenberg-Roberg V, Bohl SR, Teipel R, von Metzler I, Engelhardt M, Shumilov E, Steinhardt M, Reinhardt HC, Oubari S, Schönland S.   +15 more
europepmc   +2 more sources